文献速递肝病

慢性乙肝及其临床分期对MASLD患者肝纤维化与肝硬化的影响

Impact of Chronic Hepatitis B and Its Clinical Phases on Liver Fibrosis and Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-04-15

该多中心研究纳入6682例MASLD患者,其中VCTE队列3979例(351例合并CHB)、活检队列2703例(1811例合并CHB),旨在探讨CHB及其临床分期对肝纤维化/肝硬化的影响。结果显示合并CHB独立增加纤维化/肝硬化风险,且e抗原阳性免疫活动期及灰区CHB风险最高。

要点

  • 合并CHB使MASLD患者显著纤维化、进展期纤维化和肝硬化比例均升高。
  • e抗原阳性免疫活动期CHB患者发生显著纤维化、进展期纤维化和肝硬化的风险最高。
  • 灰区CHB同样与纤维化/肝硬化风险升高相关,需加强无创监测。

核心结论

  • 合并CHB不仅免疫活动期、灰区期也增加MASLD患者肝纤维化/肝硬化风险。

研究设计与样本

  • 多中心纳入2004至2025年中国19个中心接受VCTE或肝活检的MASLD患者6682例。
  • VCTE队列3979例(351例合并CHB),活检队列2703例(1811例合并CHB)。
  • 采用logistic回归及倾向性评分匹配分析CHB与纤维化/肝硬化的关联。

主要发现

  • VCTE队列中合并CHB者显著纤维化比例50.1% vs 33.5%,进展期纤维化25.4% vs 10.8%,肝硬化15.7% vs 5.4%(均P < .001)。
  • 活检队列结果与VCTE队列相似。
  • 多因素分析显示合并CHB独立增加纤维化/肝硬化风险(VCTE队列OR 1.98-3.73;活检队列OR 1.98-3.37;均P < .001)。
  • 按2018 AASLD标准,e抗原阳性免疫活动期CHB发生显著纤维化、进展期纤维化和肝硬化的OR为3.27-11.18(P ≤ .001)。
  • 灰区CHB的OR为3.05-6.95(P ≤ .001),倾向性评分匹配及2025 EASL分类后关联相似。

关键数值与推荐

  • 显著纤维化、进展期纤维化和肝硬化在VCTE队列中合并CHB者比例分别为50.1%、25.4%、15.7%。
  • e抗原阳性免疫活动期CHB的OR为3.27-11.18,灰区CHB的OR为3.05-6.95(均P ≤ .001)。

临床怎么用

  • 对MASLD合并CHB患者,尤其处于免疫活动期或灰区期者,应加强无创纤维化监测。
  • 此类患者可能需要个体化管理以延缓纤维化进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The overlap between chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) has been growing. This study aimed to explore the impact of CHB and its clinical phases on liver fibrosis/cirrhosis in patients with MASLD. METHODS: We enrolled patients with MASLD who underwent vibration-controlled transient elastography (VCTE) or liver biopsy at 19 centers in China between 2004 and 2025. Logistic regression analyses were conducted to examine the association between CHB and liver fibrosis/cirrhosis. Propensity score matching was used to adjust for potential confounders. RESULTS: A total of 6682 patients with MASLD were included, comprising 3979 VCTE-based cases (351 with concurrent CHB) and 2703 biopsy-proven cases (1811 with concurrent CHB). In the VCTE cohort, patients with MASLD and CHB had higher proportions of significant fibrosis (50.1% vs 33.5%), advanced fibrosis (25.4% vs 10.8%), and cirrhosis (15.7% vs 5.4%) (all P < .001), with similar findings in the biopsy cohort. Multivariate analyses showed that concurrent CHB independently increased the risks of fibrosis/cirrhosis in both cohorts (odds ratios [ORs]: VCTE cohort: 1.98-3.73; biopsy cohort: 1.98-3.37; all P < .001). Under the 2018 American Association for the Study of Liver Diseases criteria, hepatitis B e-antigen-positive immune-active CHB had the highest odds of significant fibrosis, advanced fibrosis, and cirrhosis (OR, 3.27-11.18; P ≤ .001), with elevated odds also observed in gray-zone CHB (OR, 3.05-6.95; P ≤ .001); associations remained similar after propensity score matching and application of the 2025 European Association for the Study of the Liver classification. CONCLUSIONS: Concurrent CHB increased liver fibrosis/cirrhosis risk in MASLD not only in the immune-active phase but also in the gray-zone phase. Patients with MASLD and concomitant active/gray-zone CHB may warrant enhanced noninvasive monitoring and individualized management to mitigate fibrotic progression.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Rui F, Zhang J, Li H, et al. Impact of Chronic Hepatitis B and Its Clinical Phases on Liver Fibrosis and Cirrhosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Clin Gastroenterol Hepatol. 2026. PMID: 41997336. doi:10.1016/j.cgh.2026.03.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。